About tiziana life sciences - TLSA
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer’s. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
TLSA At a Glance
Tiziana Life Sciences Ltd.
14/15 Conduit Street
London, Greater London W1S 2XJ
| Phone | 44-207-495-2379 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -18,431,000.00 | |
| Sector | Health Technology | Employees | 10 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TLSA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3,465.12 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.204 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.003 |
TLSA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,843,100.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TLSA Liquidity
| Current Ratio | 0.763 |
| Quick Ratio | 0.763 |
| Cash Ratio | 0.358 |
TLSA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -161.824 |
| Return on Equity | -924.323 |
| Return on Total Capital | -3,628.15 |
| Return on Invested Capital | -873.093 |
TLSA Capital Structure
| Total Debt to Total Equity | 876.923 |
| Total Debt to Total Capital | 89.764 |
| Total Debt to Total Assets | 3.967 |
| Long-Term Debt to Equity | 450.00 |
| Long-Term Debt to Total Capital | 46.063 |